A seed-stage company that raised $13 million less than two years ago locked in a collaboration worth up to $100 million per nominated target on August 15, 2026, when Aizen Therapeutics announced a multi-program deal with an unnamed San Diego-based public biotech. The agreement tasks Aizen's DaX foundation model with designing oral peptide therapeutics against validated targets in immunology and neurology, and it hands the company several million dollars in upfront revenue before a single molecule enters a living system.
The partner's identity does not appear in any public filing reviewed by this desk. What is public: Aizen will run DaX design cycles against multiple disease-relevant targets simultaneously, and each target that clears nomination triggers a separate milestone track capped at $100 million. The structure was confirmed in a PR Newswire release and independently reported by PeptideSTIL, which described the upfront payment as "several million dollars" and the per-target ceiling as milestone-contingent rather than guaranteed.
DaX was built at Caltech, where Aizen scientific founder David Van Valen holds a professorship. The platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid peptide chemical space—building blocks outside the standard 20 encoded by the genetic code—at ten times the scale of conventional discovery methods, according to the company. Incorporating those non-canonical residues into peptide backbones can improve metabolic stability and oral bioavailability, the two properties that have historically confined peptide drugs to injection.
Figure 1: Biomedical laboratory assay and analytical documentation.
Ajay Kshatriya, Aizen's CEO and co-founder, tied the collaboration directly to that delivery problem. "We are focused on designing oral peptides for validated biological targets that can deliver an improved therapeutic index, reduced systemic toxicity, and enhanced target engagement in a pill," Kshatriya said in the announcement. Van Valen framed the computational side: "With technical challenges in data scarcity and chemical complexity, de novo peptide design is the frontier of Drug Discovery AI."
The therapeutic gap Aizen is targeting is real but narrow. Approved oral agents in neurology, including CGRP receptor antagonists such as atogepant, are small-molecule-class compounds rather than true biologics, which illustrates how much translational space Aizen is trying to occupy, Clinical Trial Vanguard reported. Injectable biologics dominate current immunology treatment, and no approved oral biologic bridges the two categories. The collaboration's first job is to demonstrate that DaX-designed oral peptides actually engage their targets in vivo—exactly what the partner's upfront payment is funding.
That proof-of-activity hurdle is the deal's central near-term risk. The $100 million figure per target is a contractual ceiling contingent on successful nomination, preclinical advancement, and subsequent development milestones. Until in vivo target-engagement data appear, the research peptides produced by DaX remain computational designs awaiting biological confirmation. The broader custom peptide synthesis and analytical infrastructure that any advancing candidate would require is being built out in parallel across the industry, though no specific manufacturing or testing partner has been named in connection with this deal.
Aizen's next public milestone is the release of proof-of-activity data showing in vivo target engagement for its first nominated candidates. The unnamed San Diego partner will decide whether to advance any nominated target into IND-enabling studies based on those results, and that decision—not the $100 million ceiling—will determine whether DaX-designed oral peptides move from computation into clinic.
